Mike Glover

356 posts

Mike Glover banner
Mike Glover

Mike Glover

@glovedoc

Genitourinary medical oncologist @mdandersonnews. Likes: clinical trials, cycling, Miami hurricanes, Jeopardy!

Houston, TX Katılım Temmuz 2018
489 Takip Edilen431 Takipçiler
Mike Glover retweetledi
Matt Campbell MD, MS
Matt Campbell MD, MS@DocMattCampbell·
Stomp Out Cancer in honor of Dan Hund and his battle against adrenal cancer is in its 6th year stompoutcancer4dan.com all funds support rare tumor research with a new trial. Fill out a bracket at ESPN group is Dan Hund Memorial password stompoutcancer.
English
0
4
6
271
Mike Glover retweetledi
Nabil Adra
Nabil Adra@nabiladra·
PhaseII trial of cabozantinib in refractory germ-cell tumors. Nice to see activity and clinical benefit in very refractory/heavily pretreated population. Important to continue drug development in this disease! @JenniferKingMD @IUCancerCenter @TestesCancer @TestesCancer
Nabil Adra tweet mediaNabil Adra tweet mediaNabil Adra tweet media
English
0
5
18
693
Mike Glover retweetledi
Matt Campbell MD, MS
Matt Campbell MD, MS@DocMattCampbell·
@DrZachariahT two posters today focused on GCT. 1) Somatic transformation (ST) is common as initial presentation in mediastinal NSGCT and is uniformly sarcoma. AdenoCA is a late transformation event 2) ctDNA can be detected in marker negative patients including ST pts #GU26
Matt Campbell MD, MS tweet mediaMatt Campbell MD, MS tweet media
English
2
7
15
1.3K
Mike Glover retweetledi
Matt Campbell MD, MS
Matt Campbell MD, MS@DocMattCampbell·
At #GU26 a tremendous overview of optimal trial design by @PavlosMsaouel. Pavlos has repeatedly shown that even in very rare cancers, optimally designed studies can rapidly led to practice changing findings. A visionary in our field.
Matt Campbell MD, MS tweet mediaMatt Campbell MD, MS tweet mediaMatt Campbell MD, MS tweet media
English
2
19
54
8.4K
Mike Glover
Mike Glover@glovedoc·
Great talk @DrBenTran #GU26 with a study of Mi-RNA371 in stage 1 testicular cancer. How to practically integrate this test and balance vs tissue informed approach remains to be seen
Mike Glover tweet mediaMike Glover tweet mediaMike Glover tweet media
English
0
3
8
245
Mike Glover retweetledi
Matt Campbell MD, MS
Matt Campbell MD, MS@DocMattCampbell·
Very proud of @DrZachariahT, a fantastic postdoc, and his great work on timing of enfortumab vedotin plus pembrolizumab toxicity and impact on outcome led by @OAlhalabiMD at #GU26
Matt Campbell MD, MS tweet mediaMatt Campbell MD, MS tweet media
English
2
9
31
2K
Mike Glover
Mike Glover@glovedoc·
@EricTopol Per protocol is confounded as well. PCP probably more likely to use this tool if they suspect the diagnosis for other reasons
English
0
0
1
268
Eric Topol
Eric Topol@EricTopol·
An AI stethoscope for primary care doctors was assessed in a randomized, controlled trial of >1.5 million patients to detect heart failure, valve disease and AF. It didn't help make the diagnoses. Because it wasn't used enough by the doctors. It improved diagnoses when it was used. New @TheLancet, an important lesson for AI med trials thelancet.com/journals/lance…
Eric Topol tweet media
English
14
88
425
61.1K
William Shi
William Shi@williamyshi·
Finally pee(r)-reviewed in @CellCellPress! Shoutout @Kevinjliu_, @mohamshah. Gratitude to @max_diehn @AshAlizadeh @liaojoe1 and all lab members for their mentorship and support, @arkhaki Eila Skinner @StanfordUrology and all co-authors. Excited to see it out in press!
Max Diehn, MD/PhD@max_diehn

We’re excited to share our latest study describing a new urine tumor DNA (utDNA) liquid biopsy method for #BladderCancer that accounts for the field effect, a key challenge for urine MRD detection. Out today in @Cell: authors.elsevier.com/c/1mWEl_278y-E… 🧵 (1/14) #LiquidBiopsy

English
4
6
47
8.1K
Mike Glover
Mike Glover@glovedoc·
@aphysicist If the data from MRI was perfect (its not) and we had effective treatment options for every scenario (we don't) then i would agree. but thats not reality
English
1
0
4
219
Aaron Slodov
Aaron Slodov@aphysicist·
i think the reason there are a million counterfactual anecdotes with said data is because we haven't had the ability to process it effectively for patients into treatment, plus the sheer amount of anxiety that exists in medicine is overwhelming for people. it's going to take a long time
English
5
0
9
542
Mike Glover
Mike Glover@glovedoc·
@aphysicist Sorry Aaron, I disagree. There are a million counterfactual anecdotes, but the broader question is what data is there that (most) screening actually improve outcomes or changes the course?
English
5
0
17
511
Aaron Slodov
Aaron Slodov@aphysicist·
they also like to use the excuse that there are may false positives, but in medicine having more information is always better than not.
English
37
0
166
4.9K
Mike Glover
Mike Glover@glovedoc·
@AshAlizadeh Congrats! Really moving the field forward. A testament to your hard work
English
0
0
2
102
Ash Alizadeh, MD/PhD 🇺🇸
Ash Alizadeh, MD/PhD 🇺🇸@AshAlizadeh·
What a momentous partnership toward building on both companies’ momentum and resources to make meaningful progress for our patients with cancers, and to continue the impactful shifts for our field.
Foresight Diagnostics Inc.@ForesightDx

Foresight Diagnostics is now part of @NateraGenetics, uniting Natera’s best-in-class precision diagnostics portfolio and commercial and operational infrastructure with our innovative phased-variant ctDNA-MRD technology and lymphoma leadership. Read more: foresight-dx.com/press_releases…

English
6
5
29
4.6K
Mike Glover
Mike Glover@glovedoc·
Very important trial, both in outcomes and in lessons on how to run trials in rare diseases. Take advantage of the wealth of knowledge each patient brings and be kind/generous with knowledge
Pavlos Msaouel@PavlosMsaouel

1/5 Our new @NatureComms study reports the first-ever dedicated clinical trial for #RenalMedullaryCarcinoma (RMC): phase II trial of #nivolumab + #ipilimumab and what it taught us about hyperprogression to immunotherapy: nature.com/articles/s4146… #endRMC #MsaouelLab @MDAndersonNews

English
2
4
16
4K
Mike Glover retweetledi
Pavlos Msaouel
Pavlos Msaouel@PavlosMsaouel·
#IVORY is indeed the first trial of a PD(L1) x VEGF bispecific in the GU space and is generating key clinical and biological correlative data to inform further development: pmc.ncbi.nlm.nih.gov/articles/PMC12… @NazliDizman @OncHahn @glovedoc @andrewjohnsmd @DocMattCampbell @perelli_luigi
Uromigos@Uromigos

Here at #UromigosLive 2025 in our Walking around Nashville Series, @tompowles1 and @brian_rini go through PD (L1)x VEGF Bispecifics in front of the famous Batman Building. @lalaniMD @AmandaNizamMD @DrKarineTawagi @nataliagandur @ReneeSaliby @NazliDizman @uromigosjapan @TresUramigas @WeOncologists

English
1
10
28
4.9K

Keşfet

@VuMedi @DocMattCampbell @OAlhalabiMD @CYJiangMD @andrewjohnsmd @JenniferKingMD @IUCancerCenter @TestesCancer